Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to ...

In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and ...

Real-world data confirmed the findings of JAVELIN Renal 101, supporting the combination of avelumab and axitinib in advanced renal cell carcinoma (RCC), said Axel Merseburger, MD, University Hospital ...

An analysis of blood and tumor samples from patients in a clinical trial comparing two therapies for advanced renal cell carcinoma shows that different immunomodulatory mechanisms are at work ...

The PROBE trial (NCT04510597), due in 2033, will compare deferred CN versus no CN in patients receiving upfront nivolumab, pembrolizumab-axitinib, or avelumab-axitinib.